US Pharma giant Pfizer is in the final stages of an agreement with India to supply anti-COVID-19 vaccines, CEO Dr Albert Bourla said on Tuesday, observing that the domestically manufactured vaccines would be the backbone of vaccinating the Indian people.
Addressing the 15th edition of the India-US Bio Pharma & Healthcare Summit being organised by the US-India Chamber of Commerce, Dr Bourla also said that Pfizer has made a specific plan that the mid and low-income countries, which includes India, will receive at least two billion of such doses.
“My hope is that very soon we will finalise the approval of the product in India by the Indian health care authorities and the agreement with the government so that we can also start sending vaccines, on our side,” Bourla said.
The Pfizer CEO said that a significant local manufacturing of vaccines that is happening at the Serum Institute of India will provide the ‘backbone of vaccinating’ the Indian people.
“But getting the additional mRNA vaccines from us and also from Moderna will contribute significantly,” he said. Pfizer, he said, is confident of producing three billion doses of COVID-19 vaccines and another four billion by next year, making it seven billion in all.
Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.
Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.
Stay connected with us on social media platform for instant update click here to join our Twitter, & Facebook
We are now on Telegram. Click here to join our channel (@TechiUpdate) and stay updated with the latest Technology headlines.
For all the latest Life Style News Click Here
For the latest news and updates, follow us on Google News.